USA - NASDAQ:NXL - US65345B2016 - Common Stock
The current stock price of NXL is 1.25 USD. In the past month the price decreased by -16.67%. In the past year, price decreased by -67.11%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.04 | 217.47B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.62 | 196.37B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.58 | 146.77B | ||
| SYK | STRYKER CORP | 26.86 | 135.27B | ||
| IDXX | IDEXX LABORATORIES INC | 56.6 | 57.10B | ||
| BDX | BECTON DICKINSON AND CO | 12.43 | 50.85B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.08 | 48.40B | ||
| RMD | RESMED INC | 25.22 | 36.43B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.16 | 33.86B | ||
| DXCM | DEXCOM INC | 31.19 | 22.75B | ||
| PODD | INSULET CORP | 76.45 | 22.76B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.94 | 17.53B |
Nexalin Technology, Inc. designs and develops neurostimulation products. The company is headquartered in Houston, Texas and currently employs 6 full-time employees. The company went IPO on 2022-09-16. The firm has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. The company has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
NEXALIN TECHNOLOGY INC
1776 Yorktown, Suite 550
Houston TEXAS US
Employees: 6
Phone: 18322600222
Nexalin Technology, Inc. designs and develops neurostimulation products. The company is headquartered in Houston, Texas and currently employs 6 full-time employees. The company went IPO on 2022-09-16. The firm has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. The company has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
The current stock price of NXL is 1.25 USD. The price decreased by -5.3% in the last trading session.
NXL does not pay a dividend.
NXL has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
NEXALIN TECHNOLOGY INC (NXL) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
NEXALIN TECHNOLOGY INC (NXL) currently has 6 employees.
NEXALIN TECHNOLOGY INC (NXL) has a market capitalization of 22.74M USD. This makes NXL a Nano Cap stock.
ChartMill assigns a technical rating of 4 / 10 to NXL. When comparing the yearly performance of all stocks, NXL is a bad performer in the overall market: 81.24% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to NXL. While NXL has a great health rating, there are worries on its profitability.
Over the last trailing twelve months NXL reported a non-GAAP Earnings per Share(EPS) of -0.76. The EPS decreased by -2.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -134.84% | ||
| ROE | -148.42% | ||
| Debt/Equity | 0 |
5 analysts have analysed NXL and the average price target is 4.08 USD. This implies a price increase of 226.4% is expected in the next year compared to the current price of 1.25.
For the next year, analysts expect an EPS growth of 19.67% and a revenue growth 34.3% for NXL